IDiyas

For the Inventor, By the Inventor

Berlin, Germany

Helmut Wachtel

USPTO Granted Patents = 42

Average Co-Inventor Count = 4.3

ph-index = 12

Forward Citations = 512(Granted Patents)


Company Filing History:

goldMedal40 out of 1,384 
 
Schering Aktiengesellschaft
 patents
silverMedal2 out of 100 
 
Berlex Laboratories, Inc.
 patents

Years Active: 1977-2001

Loading Chart...
42 patents (USPTO):Explore Patents
1. 6191132 - Use of quisqualate receptor antagonists (2001-02-20),
2. 6117895 - Pharmaceutical preparations for TNF inhibition (2000-09-12),
3. 6060501 - Combined treatment of multiple sclerosis (2000-05-09),
4. 6025376 - Chiral methylphenyloxazolidinones (2000-02-15),
5. 6011060 - Chiral phenyldihydrofuranones as PDE-IV inhibitors (2000-01-04),
6. 5847010 - Treatment of multiple sclerosis (1998-12-08),
7. 5672622 - Treatment of multiple sclerosis (1997-09-30),
8. 5547958 - N-(8.alpha.-ergolinyl)-amides (1996-08-20),
9. 5411966 - 2, 13-disubstituted ergolines, their production and use in (1995-05-02),
10. 5401748 - 2,14-disubstituted ergolines, their production and use in pharmaceutical (1995-03-28),
11. 5242678 - BR*-diagnostics for monoamine receptors (1993-09-07),
12. 5219862 - 8 beta-substituted ergolines, process for their production and their use (1993-06-15),
13. 5212178 - 8.alpha.-acylamino ergolines and use as pharmaceutical agents (1993-05-18),
14. 5158957 - 2-substituted ergolines (1992-10-27),
15. 5064854 - 3,4-disubstituted phenyl heterocycles and their use (1991-11-12),

Title: Helmut Wachtel: Innovator in Pharmaceutical Patents

Introduction

Helmut Wachtel is a prominent inventor based in Berlin, Germany, recognized for his significant contributions to the pharmaceutical field. With a remarkable portfolio comprising 42 patents, Wachtel's work has been instrumental in developing new therapeutic approaches for neurological and inflammatory diseases.

Latest Patents

Two of Wachtel's latest patents showcase his innovative approach to addressing critical healthcare challenges. The first patent focuses on the use of quisqualate receptor antagonists, presenting a groundbreaking method for utilizing antagonists of the AMPA receptor complex and their physiologically compatible salts. This invention targets the prevention and treatment of Parkinson's disease and highlights the pharmaceutical applications of these compounds. The second patent involves pharmaceutical preparations aimed at tumor necrosis factor (TNF) inhibition, indicating that specific compounds of formula I play a vital role in treating TNF-mediated diseases.

Career Highlights

Wachtel’s professional journey includes significant positions at notable companies in the pharmaceutical industry, such as Schering Aktiengesellschaft and Berlex Laboratories, Inc. His tenure at these organizations has allowed him to collaborate on various projects that enhance the understanding of drug development and improve therapeutic options for patients.

Collaborations

Throughout his impressive career, Wachtel has worked alongside esteemed colleagues, including Gerhard Sauer and Wolfgang Kehr. These collaborations have fostered innovative ideas and led to advancements in research that have positively impacted patient care and treatment outcomes.

Conclusion

Helmut Wachtel's dedication to innovation in pharmaceuticals is evidenced by his substantial number of patents, reflecting his commitment to addressing critical health issues. His research not only enhances the understanding of complex diseases but also establishes new pathways for effective treatments. Wachtel's contributions continue to inspire future generations of inventors in the field of medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…